London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Moonparty - "There is no new information". Or maybe not . . . .
Does this vague report suggest that the 'delivery' is sorted out ?
Ray I agree. DNA
Any answers or thoughts -' Moving on, does the testing in mice mean the delivery is sorted ?'
Crikey Ivy - I know that. I knew that. The 'so can others' refers to not you.
I wasn't suggesting you were wrong. It's DNA.
I'm stressed - Stockport have just equalised.
Any answers or thoughts -' Moving on, does the testing in mice mean the delivery is sorted ?'
A write up in the Independent is really positive and will introduce a lot of people to Scancell. Would hope for an impact on the sp this week.
There is no new information hence no need for RNS, but to me this reaffirms that all is on track. Plus directors buying 400k shares!
All is good, just a bit more patience required. And in the meantime there's the other trials and Avidimab that I'm sure are all ready for news at any minute.
TF I can absolute clarify it is a mistake if that is good enough for you.
I agree with Bobbust if it was an official release of info, it should be an RNS, as it could be considered significant news potentially with material impact on the SP but was it a press release e.g. as in a formal interview with the journalist or just a guess by the journalist from a "conversation"?...Should we believe everything we read in the papers?
https://www.scancell.co.uk/covidity
Always has been DNA
Yes Ivy thanks and I thought that was TIC too. Thus the wink :)
But if the Indy can get it wrong, so can others. So it's best clarified IMO. DNA then.
Moving on, does the testing in mice mean the delivery is sorted ?
Morning TF,
I think Crumbs was tongue in cheek but he can clarify lol
If it was something completely new like mRNA then I would be staggered but delighted if that made sense but am sure it is just sloppy journalism not checking background info
However if they have spoken to SCLP recently and they have confirmed the positive mice results and 2H to start in human trials then that is good news and needs some confirmation.
Even a retweet of article would be interesting
The counter argument is that the research and development of a vaccine will encounter setbacks as well as successes.
What Scancell is attempting is novel and as such they will always encounter unexpected hurdles to overcome.
The last we heard is that the trial is expected to start in 2021. I don't think they can be more specific than that.
This is a first outing for both Avidimab and the delivery method. I suspect it is not easy to optimise this vaccine to achieve the goal of stopping all variants of covid19 and also perhaps other coronaviruses.
100% agree bobbust, at the very least an RNS-R maybe? Scancells comms with shareholders is terrible IMO, we should be the first to know about this kind of stuff shouldn't we?
Hi Krafty - yes the trial should be happening - between 6 and 32 weeks time. Let's hope sooner rather than later that's all.
RNS please!!!
why do we find out progress from the news papers??
"Human trials of the vaccine will begin in the second half of this year after testing on mice returned positive results."
this should be released by RNS!!
Good luck TF.
I still remember both teams on my Shoot League Ladder. The technology of its day!
CC thanks - excellent find.
Particularly this - ". . . . testing on mice returned positive results". Does that mean the vaccine is in final form and that the 'delivery' has been sorted ?
. . . and again "Human trials of the vaccine will begin in the second half of this year . . . " - well I make that about 6 weeks, (at the earliest) and 32 weeks, (at the latest). Soon please team !
All this fuss about the Cup Final - the big game is today at 12.15 on BT Sport, Stockport v Torquay Utd.
(BTW I thought Chelsea didn't get the run of the ball but well done Leicester City and it's Thai owners).
Nice day all.
Crumbs is that right ? Ivy comments in 39241 - "a great mention and great publicity for SCLP but before anyone else says it is not mRNA based so I just think the reporters have not done enough research or checked the facts". So ??
Brilliant to be in the mRNA game now :)
Pan-coronavirus vaccine breakthrough in the fight against future pandemics .
In the UK, Scientists from the University of Nottingham and a company called Scancell are working to develop an mRNA-base jab specific to all Covid variants their vaccine targets the conserved core of SARS coV-2 called the nucleocapsid as well as the spike protein which is the main site of the mutations that have been detected to date.
Dr Gillies O'Bryan-Tear, Scancell chief medical officer,
"What's been mutated in the pandemic has been the spike protein, which alters the transmissibility of the virus and can alter it's ability to resist either the immunity required by natural infection or vaccination."
"The difference between our technology and most others is that as well as targeting the spike protein,we have another specificity in our vaccine which targets the nucleocapsid protein. This is the body of the virus.We don't think it mutates as much as the spike does so there's a chance it could work across different variants irrispective of the spike protein mutations."
Human trials of the vaccine will begin in the second half of this year after testing on mice returned positive results.
https://www.pressreader.com/uk/the-independent-1029/20210516/281651077996649